GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (FRA:19X) » Definitions » Cyclically Adjusted PB Ratio

Axsome Therapeutics (FRA:19X) Cyclically Adjusted PB Ratio : 34.87 (As of Jun. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Axsome Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Axsome Therapeutics's current share price is €68.00. Axsome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €1.95. Axsome Therapeutics's Cyclically Adjusted PB Ratio for today is 34.87.

The historical rank and industry rank for Axsome Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:19X' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 32.03   Med: 38.62   Max: 48.45
Current: 34.67

During the past years, Axsome Therapeutics's highest Cyclically Adjusted PB Ratio was 48.45. The lowest was 32.03. And the median was 38.62.

FRA:19X's Cyclically Adjusted PB Ratio is ranked worse than
98.63% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs FRA:19X: 34.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Axsome Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €2.792. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.95 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Axsome Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Axsome Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Cyclically Adjusted PB Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 39.89

Axsome Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 39.89 37.65

Competitive Comparison of Axsome Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Axsome Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Cyclically Adjusted PB Ratio falls into.



Axsome Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Axsome Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=68.00/1.95
=34.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Axsome Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.792/131.7762*131.7762
=2.792

Current CPI (Mar. 2024) = 131.7762.

Axsome Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -0.204 99.070 -0.271
201503 0.000 99.621 0.000
201506 -0.363 100.684 -0.475
201509 0.196 100.392 0.257
201512 2.226 99.792 2.939
201603 1.934 100.470 2.537
201606 1.622 101.688 2.102
201609 1.311 101.861 1.696
201612 1.067 101.863 1.380
201703 1.163 102.862 1.490
201706 0.858 103.349 1.094
201709 0.597 104.136 0.755
201712 0.554 104.011 0.702
201803 0.399 105.290 0.499
201806 0.229 106.317 0.284
201809 0.024 106.507 0.030
201812 0.027 105.998 0.034
201903 0.462 107.251 0.568
201906 0.626 108.070 0.763
201909 0.180 108.329 0.219
201912 4.355 108.420 5.293
202003 3.812 108.902 4.613
202006 3.675 108.767 4.452
202009 3.075 109.815 3.690
202012 2.503 109.897 3.001
202103 2.153 111.754 2.539
202106 1.575 114.631 1.811
202109 0.963 115.734 1.096
202112 0.366 117.630 0.410
202203 0.343 121.301 0.373
202206 0.360 125.017 0.379
202209 3.660 125.227 3.851
202212 2.378 125.222 2.502
202303 2.398 127.348 2.481
202306 5.525 128.729 5.656
202309 5.337 129.860 5.416
202312 3.698 129.419 3.765
202403 2.792 131.776 2.792

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Axsome Therapeutics  (FRA:19X) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Axsome Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics (FRA:19X) Business Description

Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Axsome Therapeutics (FRA:19X) Headlines

No Headlines